Insomnia is a common health problem affecting approximately 10–30% of the global population. It most often manifests as difficulty falling asleep (60.2%), nighttime awakenings or early morning awakenings (26.4%). For example, in the United States, 10–15% of adults regularly experience symptoms of insomnia, and 2–3% meet the diagnostic criteria for chronic insomnia. In Poland, this problem is even more serious, as it is estimated to affect approximately 24–25% of adults, with a higher prevalence in women (28.1%) than in men (18.1%). Contemporary research indicates that civilization-related factors, including stress, shift work, unhealthy lifestyle, and circadian rhythm disturbances, contribute to the worsening of sleep disorders; the COVID-19 pandemic has further exacerbated this problem. Initially, benzodiazepines (BZDs) were used to treat insomnia. Later, non-benzodiazepine hypnotics (NBZDs), also known as Z-drugs, were introduced. Currently, melatonin receptor agonists, such as melatonin, are also used; however, Z-drugs remain the predominant group of medications. The widespread use of non-benzodiazepine drugs has led to increased interest in the impact of residues of these compounds on the environment. They belong to the group of psychoactive drugs that may disrupt the normal functioning of non-target organisms. Environmental risk assessment (ERA) requires knowledge of the physicochemical and pharmacokinetic properties of these drugs, the scale of their consumption globally and in individual regions, their removal efficiency in conventional wastewater treatment plants, their environmental fate, detected environmental concentrations, and the results of ecotoxicological studies. The aim of this article is to present the most significant available literature data on this topic. This will allow for a better understanding of their circulation in the environment and the threats they pose to ecosystems. The final remarks discuss the key challenges in this field.